Second-degree Heart Block in a Patient on Zanubrutinib
1 Department of Internal Medicine, HCA Healthcare; MountainView Hospital, Las Vegas, NV, USA.
2 Department of Critical Care, HCA Healthcare; Southern Hills Hospital, Las Vegas, NV, USA.
Case Study
World Journal of Advanced Research and Reviews, 2024, 22(02), 1371–1373
Publication history:
Received on 08 April 2024; revised on 16 May 2024; accepted on 18 May 2024
Abstract:
Zanubrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor recently approved by the Food and Drug Administration for treatment of chronic lymphocytic leukemia (CLL) in January 2023. As a second generation BTK inhibitor, zanubrutinib is more selective for “on-target” BTK and have less cardiac side effects. Although atrial flutter and atrial fibrillation were noted side effects during clinical trials, heart block is not a known side effect. Here we present a case of a patient with CLL on zanubrutinib who presented with a second-degree heart block.
Keywords:
CLL; Zanubrutinib; Heart block; Second-degree heart block; BTK inhibitor
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0